Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. Currently, treatment selection and response assessment in mCRPC still rely largely on prostate-specific ...

Clear Cell Renal cell carcinoma (ccRCC) is the most common form of kidney cancer. The VHL tumor suppressor is lost or mutated in the majority of ccRCC and hereditary mutations in VHL predispose ...

Alicia Morgans outlines anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk ...

Shilpa Gupta reports 3.5-year follow-up data from EV-302. Among all patients, 44% remained alive, double the chemotherapy arm, and more than 70% of complete responders were still alive. Complete ...

Kim Chi describes KLK2-comPAS, a trial investigating pasritamig, a bispecific IgG1 antibody that binds KLK2 and CD3. Phase one and two data in heavily pretreated patients showed radiographic ...

Talazoparib plus enzalutamide improved overall survival (OS) in the biomarker-unselected TALAPRO-2 population, but OS benefit was not statistically significant in the homologous recombination repair ...

Over the past decades, both hypofractionation and (focal) dose escalation have been studied in trials for prostate cancer (PCa) radiotherapy. Several studies have demonstrated a benefit of dose ...

Prostate cancer is characterized by profound clinical and molecular heterogeneity. While its genomic heterogeneity is well-characterized, its epigenomic heterogeneity remains less understood. We ...

To evaluate current adoption of guidelines for low- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC) in the UK and to assess clinicians' ability to apply their chosen guideline ...

Proton beam therapy (PBT) offers a unique dosimetric advantage over photon-based external beam radiotherapy by concentrating dose at a certain depth (the Bragg peak) and markedly reducing the exit ...

At the 2026 UCSF-UCLA PSMA Conference, Jonathan Chou reviews non-PARP DNA repair targets as radiosensitizers for radiopharmaceutical therapy, highlighting a CRISPR-Cas9 functional genomics screen ...

Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide ...